Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 8/20 | 0.36 |
| ▸ | CDK7 | P50613 | 8/20 | 0.36 |
| ▸ | CDK2 | P24941 | 3/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | CCNH | P51946 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25041354 | 0.85 | ALDH1A1 (0.41) | ROCK2CDK9CDK7PDE3BPDE3A | |
| SCHEMBL25041352 | 0.82 | ROCK2 (0.49) | ROCK2CDK9CDK7PDE3BPDE3A | |
| SCHEMBL16285251 | 0.81 | POLB (0.48) | — | |
| SCHEMBL25041348 | 0.79 | CDK2 (0.38) | ROCK2CDK2MAPKAPK2PDE3BPDE3A | |
| SCHEMBL30279117 | 0.79 | CDK2 (0.38) | ROCK2CDK2MAPKAPK2PDE3BPDE3A | |
| SCHEMBL25040038 | 0.74 | EPHX1 (0.42) | KDM1AMAOB | |
| SCHEMBL25040031 | 0.74 | EPHX1 (0.42) | KDM1AMAOB | |
| SCHEMBL25039545 | 0.74 | EPHX1 (0.42) | KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL29218729 | 0.73 | EPHX1 (0.41) | KDM1AMAOB | |
| SCHEMBL25041421 | 0.73 | MALT1 (0.43) | KDM1AMAOBCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-10-31 | — | — | US | disclosed |
| EP-4384493-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023016447-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023016447-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | AIFM2, GPX1, GPX4 | ROCK2 1973/4885CDK9 3679/4885CDK7 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.